Loading…
← CockpitCompetitor Analysis › 688639.SS Anhui Huaheng Biotechnology Co., Ltd. Class AOpen in the cockpit ↗

Anhui Huaheng Biotechnology Co., Ltd. Class A688639.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology
Momentum weak 24
Mkt cap
$605M
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$13.3M
20-day average traded
Fwd P/E
22.3×
forward earnings
ROIC−WACC
-2.3 pp
WACC 7.6%
Hurdle
n/a
no reverse DCF
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥14.90
1D-1.3%
1W-9.3%
1M-17.0%
3M-15.1%
6M-45.0%
YTD-54.3%
1Y-57.1%
ATR %5.2%
52w lowhigh65.8% off high

What Anhui Huaheng Biotechnology does

Employees: 2,252

Anhui Huaheng Biotechnology at a glance

Size Anhui Huaheng Biotechnology (688639.SS) is a China Health Care company (Biotechnology) with a market value of $605M, the 3220th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.90 on 18 Nov 2026.

Performance Over six months the shares fell 45.0%, against -22.0% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth Revenue grew 7.5% over the last twelve months (peer median +23.1%); the operating margin is 3.5% (peer median -111.2%).

Valuation It trades at 22.3× forward earnings against a peer median of 21.6× (4th cheapest of 7).

Capital Return on invested capital runs 2.3 points below its cost of capital (7.6% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 79688639.SS 56
Six months, rebased to 100: Anhui Huaheng Biotechnology against the median of its 20 peers (local-currency closes).

Anhui Huaheng Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.04BCN¥2.86BCN¥2.18BCN¥1.94BCN¥1.42B
Revenue growth—+31%+12%+37%—
Gross profitCN¥766MCN¥560MCN¥511MCN¥756MCN¥533M
EBITDAn/aCN¥368MCN¥330MCN¥589MCN¥376M
Net incomeCN¥96.1MCN¥132MCN¥190MCN¥449MCN¥320M
Free cash flow-CN¥397M-CN¥531M-CN¥724M-CN¥965M-CN¥90.3M
Capital expenditureCN¥563MCN¥637MCN¥924MCN¥1.27BCN¥456M
Total debtCN¥2.47BCN¥2.10BCN¥1.58BCN¥1.30BCN¥91.2M

Quarterly statements and history in the cockpit →

Anhui Huaheng Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-100%0%+100%+200%+300%0%+50%SRZNDSGN603387JANXFDMTGERN1672GNFT300404688197SANA3008717729KURA688639.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Anhui Huaheng Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×200×400×002880GERNGNFT3004043008719966688639.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Anhui Huaheng Biotechnology is the large dot.

Anhui Huaheng Biotechnology competitors and peer comparison

How Anhui Huaheng Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Anhui Huaheng Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure688639.SSPeer medianRank in peer set
1-month return-17.0%-15.3%10th lowest of 21
6-month return-45.0%-22.0%4th lowest of 20
Distance from 52-week high-65.8%-46.1%5th lowest of 21
Revenue growth (TTM)+7.5%+23.1%7th lowest of 17
Operating margin3.5%-111.2%5th highest of 17
Forward P/E22.3×21.6×4th cheapest of 7
ROIC minus cost of capital-2.3 pp-15.2 pp4th highest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%22.3×n/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%n/an/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Alebund Pharmaceuticals (Jiangsu) 9637.HKHong Kong$595Mn/a+674%-495%n/an/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%n/a-8.9%-1.3%
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%19.2×n/an/a
4D Molecular Therapeutics FDMTUnited States$578M+23%+79,952%-226%n/an/an/a
Geron GERNUnited States$638M-21%+19%-8%17.4×n/an/a
Ascletis Pharma 1672.HKHong Kong$571M-72%-59%-71,976%n/an/an/a
Genfit GNFT.PAFrance$571M+22%+28%-130%431.5×39.8%+143.5%
Boji Medical Technology 300404.SZChina$561M-6%+32%4%69.3×31.9%+27.2%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%n/an/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%n/a40.3%+21.5%
Sana Biotechnology SANAUnited States$554M-41%n/an/an/an/an/a
Hvsen Biotechnology 300871.SZChina$553M-22%+2%17%11.7×n/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%24.0×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Wave Life Sciences WVEUnited States$546M-55%-35%-321%n/an/an/a
Climb Bio CLYMUnited States$546M-12%n/an/an/an/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%n/an/an/a

Questions

Which companies are Anhui Huaheng Biotechnology's closest peers?
The cockpit's peer set: Surrozen (SRZN), Design Therapeutics (DSGN), Alebund Pharmaceuticals (Jiangsu) (9637.HK), Getein Biotech (603387.SS), Janux Therapeutics (JANX), Shenzhen Weiguang Biological Products (002880.SZ), 4D Molecular Therapeutics (FDMT), Geron (GERN).
Is Anhui Huaheng Biotechnology expensive compared with its peers?
On forward p/e it trades at 22.3× against a peer median of 21.6×, 4th cheapest of 7 in its peer set.
How has Anhui Huaheng Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -45.0% against -22.0% for the median peer; over one year -57.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.